Arsenic-Related Cancers: A Comprehensive Disease Characteristics Report

Summary

Arsenic-related cancers represent a group of malignancies caused by chronic exposure to inorganic arsenic, classified as an IARC Group 1 human carcinogen. The primary cancer types include skin cancer (squamous cell carcinoma, basal cell carcinoma, Bowen's disease), lung cancer, bladder cancer, liver cancer (hepatocellular carcinoma, angiosarcoma), and kidney cancer, with emerging evidence for gallbladder, cholangiocarcinoma, and upper urinary tract cancers. More than 200 million people worldwide are chronically exposed to arsenic concentrations in drinking water exceeding the WHO threshold of 10 μg/L, making this one of the most significant environmental carcinogenesis challenges globally. The global burden is estimated at approximately 1.4 million disability-adjusted life years (DALYs) annually from arsenic-related cancers attributable to food alone.

The carcinogenic mechanism of arsenic is distinctive among known carcinogens: it is fundamentally epigenetic and non-mutagenic. Arsenic does not cause point mutations but instead induces chromosomal aberrations, disrupts DNA methylation through depletion of S-adenosylmethionine (SAM), alters histone modifications (notably loss of H4K16ac), dysregulates miRNA expression, inhibits DNA repair, and generates oxidative stress. Genetic variation in AS3MT (arsenic [+3 oxidation state] methyltransferase), the key enzyme in arsenic biotransformation, is the strongest determinant of inter-individual cancer susceptibility, with genome-wide significant associations at the 10q24.32 locus. Individuals who methylate arsenic inefficiently (high urinary monomethylarsonic acid percentage) face substantially elevated cancer risks.

A critical and clinically alarming feature is the extraordinary latency of arsenic carcinogenesis: cancer risks remain elevated for 40+ years after exposure cessation, with lung cancer relative risks of 3.38 and bladder cancer relative risks of 4.79 still observed decades after the cessation of high-dose exposure in northern Chile. Primary prevention through water supply mitigation is the most effective intervention, though benefits take decades to fully materialize. The synergistic interaction between arsenic and tobacco smoking (70-130% excess above additive effects for lung cancer) underscores the need for integrated public health approaches targeting both exposures simultaneously.

1. Disease Information

Overview

Arsenic-related cancers are malignancies arising from chronic exposure to inorganic arsenic (iAs), primarily through contaminated drinking water, but also via contaminated food, occupational exposures, and iatrogenic sources (traditional medicines). Inorganic arsenic is classified as a Group 1 human carcinogen by the International Agency for Research on Cancer (IARC), with established causal links to cancers of the skin, lung, urinary bladder, liver, and kidney.

The disease entity is not a single cancer but rather a spectrum of malignancies sharing a common etiological agent. The most characteristic manifestation is the triad of arsenical skin lesions: hyperpigmentation/depigmentation, hyperkeratosis (arsenical keratoses), and Bowen's disease (squamous cell carcinoma in situ), which may progress to invasive squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).

As stated in a comprehensive review: "Epidemiological studies have established a strong association between inorganic arsenic (iAs) exposure in drinking water and an increased incidence of cancer including bladder, liver, lung, prostate, and skin cancer" (PMID: 30223072).

Key Identifiers

Synonyms and Alternative Names

• Arsenical cancers
• Arsenic-induced malignancies
• Cancers associated with chronic arsenicosis
• Arsenical keratosis-associated carcinomas (for skin)
• Blackfoot disease-associated cancers (historical, Taiwan)
• Hydroarsenicism-related cancers (Latin America)

Data Sources

Information is derived from aggregated disease-level resources including large-scale epidemiological cohort and case-control studies (Taiwan Blackfoot Disease endemic area studies, northern Chile studies, Bangladesh Health Effects of Arsenic Longitudinal Study), cancer registries (Taiwan Cancer Registry, SEER), and ecological studies. Individual patient data from clinical series and case reports supplement the aggregate data.

2. Etiology

Disease Causal Factors

The primary causal factor is chronic exposure to inorganic arsenic, predominantly through contaminated drinking water. Arsenic is an environmental carcinogen; the disease is not inherited but results from prolonged environmental exposure interacting with individual genetic susceptibility.

As reviewed comprehensively by Hubaux et al. (2013): arsenic, asbestos, and radon are "three prominent non-tobacco carcinogens strongly associated with lung cancer. Exposure to these agents can lead to genetic and epigenetic alterations in tumor genomes, impacting genes and pathways involved in lung cancer development" (PMID: 23173984).

Risk Factors

Environmental Risk Factors

Genetic Risk Factors

• AS3MT (arsenic [+3 oxidation state] methyltransferase) polymorphisms at 10q24.32: The first GWAS on arsenic metabolism identified "genome-wide significant association signals (P<5×10^-8) for percentages of both monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA) near the AS3MT gene (arsenite methyltransferase; 10q24.32), with five genetic variants showing independent associations" (PMID: 22383894). Specific variants:
• rs3740393: Carriers had lower %MMA (-1.9%), higher %DMA (+4.0%), and lower bladder cancer odds (OR=0.3, 95% CI: 0.1-0.6) (PMID: 28640505)
• rs11191439 (Met287Thr): C allele carriers had elevated bladder cancer risk (OR=1.17; 95% CI: 1.04-1.32 per 1 μg/L increase in arsenic) (PMID: 22747749)
• rs9527: Associated with skin lesion risk (P=0.0005)
• rs11191438, rs10748835, rs1046778: Multiple AS3MT SNPs associated with bladder cancer risk through haplotype combinations (PMID: 29669044)
• MTHFR (methylenetetrahydrofolate reductase): rs1476413 A/A homozygotes had 60% lower bladder cancer risk (OR=0.40; 95% CI: 0.18-0.88) (PMID: 22747749)
• GSTO1/2 (glutathione S-transferase omega): GSTO2 polymorphisms influence inorganic arsenic percentage in urine (PMID: 19680750)
• PNP (purine nucleoside phosphorylase): Significant gene effects on DMA% (PMID: 19680750)
• N6AMT1: rs1997605 A allele associated with decreased GDM risk (OR=0.46), with effects mediated through arsenic methylation efficiency (PMID: 36681142)

Protective Factors

Genetic Protective Factors

• AS3MT efficient methylation haplotypes: The CCTC haplotype (based on rs3740400, rs3740393, rs11191439, rs1046778) was associated with lower %iAs and %MMA and showed no increased BCC risk with arsenic exposure (OR=1.0, CI 0.9-1.2) (PMID: 25156000)
• MTHFR variants: Certain alleles that enhance one-carbon metabolism and folate cycling

Environmental Protective Factors

• Selenium: Organoselenium blocked arsenic cancer enhancement in mouse models. "Supplemental Se was uncommonly effective at preventing even a trace of As in skin at 14 or 196 days of continuous exposure to As in drinking water" (PMID: 18560523)
• Folate and B vitamins: Folate intake modifies arsenic methylation efficiency; adequate folate status supports the secondary methylation pathway (PMID: 40441120)
• Adequate nutritional status: Manganese, zinc, and ferritin levels affect the association between arsenic methylation efficiency and health outcomes (PMID: 34662579)
• Clean water access: The most effective protective intervention

Gene-Environment Interactions

The central gene-environment interaction in arsenic carcinogenesis involves AS3MT genetic variation modifying the efficiency of arsenic biotransformation, which in turn determines the internal dose of toxic methylated trivalent metabolites. Key evidence:

• Individuals with AS3MT rs3740393 minor alleles had both more efficient arsenic methylation AND lower cancer risk, demonstrating that the genetic effect on cancer operates through the metabolic pathway (PMID: 28640505)
• AS3MT haplotypes modify arsenic metabolism, and "the fact that AS3MT haplotype status modified arsenic metabolism, and in turn the arsenic-related BCC risk, supports a causal relationship between low-level arsenic exposure and BCC" (PMID: 25156000)
• Arsenic-smoking synergism is dose-dependent: "The interaction between arsenic exposure and tobacco smoke seems to be negligible at low arsenic concentrations (<100 μg/L), while there is a synergistic effect at higher concentrations" (PMID: 36901176)

3. Phenotypes

Skin Manifestations (Primary Target Organ)

Arsenical Keratoses

• Type: Physical manifestation / precancerous lesion
• HPO: HP:0000966 (Hyperpigmentation of the skin), HP:0000962 (Hyperkeratosis), HP:0007479 (Diffuse palmoplantar keratosis)
• Characteristics: Onset 5-10 years after exposure; punctate keratoses on palms and soles; prevalence 92-98% in chronically exposed populations; progressive from mild to severe; precancerous with ~53% progressing to malignancy in some series
• Frequency: Near-universal in heavily exposed individuals (>300 μg/L for years)
• QoL impact: Painful keratoses on palms/soles impair manual work and ambulation

Bowen's Disease (SCC in situ)

• Type: Precancerous/malignant skin lesion
• HPO: HP:0008066 (Abnormal blistering of the skin); MONDO: squamous cell carcinoma in situ
• Characteristics: Adult-onset (typically decades after exposure); erythematous scaly patches, often multicentric; 37.5% of cutaneous malignancies in one Indian series (PMID: 24053006); can progress to invasive SCC
• QoL impact: Cosmetic disfigurement, psychological distress, cancer anxiety

Squamous Cell Carcinoma

• Type: Malignant neoplasm
• HPO: HP:0006739 (Squamous cell carcinoma of the skin)
• Characteristics: Most common arsenic-related malignancy in some series (41.7%); occurs on trunk, extremities; can be multicentric; metastatic potential
• QoL impact: Severe; surgical treatment may impair function; metastatic disease life-threatening

Basal Cell Carcinoma

• Type: Malignant neoplasm
• HPO: HP:0002671 (Basal cell carcinoma)
• Characteristics: Often superficial, multiple lesions on trunk; 33.3% of cutaneous malignancies (PMID: 24053006); dose-response with arsenic exposure
• QoL impact: Moderate; locally destructive but rarely metastasizes

Pigmentation Changes

• Type: Physical manifestation
• HPO: HP:0000953 (Hyperpigmentation of the skin), HP:0001010 (Hypopigmentation of the skin)
• Characteristics: "Rain-drop" pattern (diffuse hyperpigmentation with scattered hypopigmented macules); among the earliest signs; 88% hyperpigmentation, 56% hypopigmentation in Chinese series (PMID: 39189802)

Internal Cancers

Lung Cancer

• Type: Malignant neoplasm
• HPO: HP:0100526 (Neoplasm of the lung)
• Characteristics: Adenocarcinoma and SCC subtypes; latency 20-40+ years; OR=4.32 (95% CI 2.60-7.17) at highest exposures; lung cancer accounts for 10-25% of never-smoker lung cancers when arsenic is involved (PMID: 23173984)
• Severity: High mortality; RR=3.38 in men still elevated 40 years post-exposure (PMID: 29069505)

Bladder Cancer (Transitional Cell Carcinoma)

• Type: Malignant neoplasm
• HPO: HP:0002862 (Bladder carcinoma)
• Characteristics: Transitional cell carcinoma predominant; strong dose-response; OR=6.50 at >335 μg/L arsenic (PMID: 23355602); RR=4.79 in men persisting 40 years post-exposure
• Biomarker: ADAM28 overexpressed in bladder TCC from Blackfoot disease areas (PMID: 21913264)

Hepatocellular Carcinoma and Angiosarcoma

• Type: Malignant neoplasm
• HPO: HP:0001402 (Hepatocellular carcinoma)
• Characteristics: HCC and angiosarcoma documented; spectrum of liver pathology from hepatoportal sclerosis to cirrhosis to carcinoma (PMID: 12426152)

Kidney Cancer

• Type: Malignant neoplasm
• HPO: HP:0009726 (Renal neoplasm)
• Characteristics: Dose-response relationship established; mortality declined after water mitigation (PMID: 16381491)

Laboratory Abnormalities

• Elevated urinary arsenic species: Total arsenic, iAs%, MMA%, DMA% measured by HPLC-HG-AAS
• Mees' lines in nails: White transverse bands; present in only ~5% of cases (PMID: 39189802)
• Elevated arsenic in hair and nails: Biomarkers of chronic exposure
• HPO: HP:0040270 (Impaired arsenic metabolism); HP:0012378 (Fatigue)

4. Genetic/Molecular Information

Causal Genes (Somatic Alterations in Arsenic-Induced Cancers)

Arsenic-related cancers are not caused by germline gene mutations; rather, arsenic induces somatic genetic and epigenetic alterations in target tissues:

• TP53: p53 pathway disrupted; arsenic induces MDM2, p53, and their phosphorylation and "affects the MDM2/p53 complex" (PMID: 35829882)
• CDKN2A (p16): Promoter CpG island hypermethylation found in 42% of arsenic-exposed individuals vs 2% in controls (PMID: 17479413)
• HRAS: Ha-ras codon-12 mutation co-occurs with Aurora-A overexpression in bladder cancer from arsenic-endemic areas; arsenic treatment increases Aurora-A expression in bladder cells (PMID: 16338065)
• FOSB: DNA methylation changes in gene body region following gestational arsenic exposure, with increased expression (PMID: 26411935)

Susceptibility Genes (Germline)

Epigenetic Information

Arsenic is a potent epimutagen that disrupts the epigenome through multiple mechanisms:

1. DNA Methylation: Arsenic biotransformation depletes S-adenosylmethionine (SAM), the universal methyl donor: "Arsenic, a xenobiotic substance, is biotransformed in the body to its methylated species by using the physiological S-adenosyl methionine (SAM). SAM dictates methylation status of the genome and arsenic metabolism leads to depletion of SAM leading to an epigenetic disequilibrium" (PMID: 25898228). This causes:
2. Global DNA hypomethylation (genomic instability)
3. Gene-specific promoter hypermethylation (tumor suppressor silencing)

4. p16 promoter methylation: 42% vs 2% in exposed vs controls (PMID: 17479413)

5. Histone Modifications: Loss of H4K16ac is a hallmark of arsenic-related cancers; increased H3K9me2 and H3S10ph observed across multiple studies (PMID: 27352015)

6. miRNA Dysregulation: Stage-specific miRNA profiles in arsenic skin lesions: miR-425-5p and miR-433 induced in both BCC and SCC (malignancy markers); miR-184 and miR-576-3p selectively induced in SCC (metastasis markers) (PMID: 30114287)

Chromosomal Abnormalities

Arsenic induces chromosomal instability (CIN) rather than point mutations: - Increased frequency of micronuclei, chromosome aberrations, and sister chromatid exchanges - Does NOT induce point mutations — a distinctive feature of arsenic genotoxicity - Mitotic errors from histone H3S10ph dysregulation contribute to aneuploidy - "Arsenic increases the frequency of micronuclei, chromosome aberrations and sister chromatid exchanges both in humans and in animals, but it does not induce point mutations" (PMID: 11885915)

5. Environmental Information

Environmental Factors

• Drinking water contamination: The primary route of exposure. Natural geological contamination affects major aquifers in Bangladesh, West Bengal (India), Taiwan, northern Chile, Argentina, Mexico, Vietnam, and parts of the United States. Pakistan has mean groundwater arsenic of 120 μg/L (range: 0.1-2090 μg/L), with 73% of studied areas exceeding WHO limits (PMID: 29990938)
• Foodborne exposure: Rice and grains are significant dietary sources; estimated ~1.4 million DALYs annually from foodborne arsenic cancers globally (PMID: 30665120)
• Occupational exposure: Copper smelting, mining, glass manufacturing, wood preservation, semiconductor manufacturing
• CHEBI terms: CHEBI:22632 (arsenic), CHEBI:35828 (arsenite), CHEBI:30621 (arsenate)

Lifestyle Factors

• Tobacco smoking: Synergistic interaction with arsenic for lung cancer. Meta-analysis showed "the joint effect from both exposures consistently exceeded the sum of the separate effects by about 70 to 130%" (PMID: 1554806). Effect is dose-dependent: synergism primarily at arsenic >100 μg/L (PMID: 36901176)
• Nutritional deficiencies: Low folate, selenium, zinc, and manganese may exacerbate arsenic toxicity
• Alcohol consumption: May compound liver damage from arsenic

Infectious Agents

Not directly applicable. However, co-exposure with other carcinogens (UV radiation, hepatitis viruses) may have additive or synergistic effects on cancer risk.

6. Mechanism / Pathophysiology

Causal Chain: From Arsenic Exposure to Cancer

EXPOSURE: Inorganic Arsenic (iAs III/V) ingested
 |
BIOTRANSFORMATION: iAs --> MMA(III/V) --> DMA(III/V)
  [Catalyzed by AS3MT, requires SAM as methyl donor, GSH as reductant]
 |
PROXIMATE CARCINOGENS: Methylated trivalent species (MMA-III, DMA-III)
  [More cytotoxic than inorganic arsenic]
 |
MOLECULAR MECHANISMS (parallel, interacting):
  |-- SAM DEPLETION --> Global DNA hypomethylation + Gene-specific hypermethylation
  |-- OXIDATIVE STRESS --> ROS --> DNA damage, lipid peroxidation
  |-- DNA REPAIR INHIBITION --> Persistence of DNA lesions
  |-- HISTONE MODIFICATION --> Loss of H4K16ac, gain of H3K9me2
  |-- miRNA DYSREGULATION --> Altered tumor suppressor/oncogene regulation
  |-- SIGNALING PATHWAY ACTIVATION --> NF-kB, MAPK, PI3K/AKT, Wnt
  +-- CHROMOSOMAL INSTABILITY --> Aneuploidy, mitotic errors
 |
CELLULAR OUTCOMES:
  |-- Tumor suppressor silencing (p16, p53 pathway disruption)
  |-- Oncogene activation (Aurora-A, Ha-ras, FOSB)
  |-- Evasion of apoptosis
  |-- Sustained proliferation
  +-- Cancer stem cell enrichment
 |
CANCER: Skin, Lung, Bladder, Liver, Kidney malignancies
  [Latency: 10-40+ years]

Molecular Pathways

• PI3K/AKT pathway: Arsenic activates AKT signaling promoting cell survival and proliferation; ATO inhibits this pathway in therapeutic contexts (PMID: 40721473)
• MAPK/ERK pathway: Arsenic activates RAS-RAF-MEK-ERK cascade
• NF-kB pathway: Chronic inflammation driven by arsenic activates NF-kB
• Wnt/beta-catenin pathway: Implicated in arsenic-induced cancer stem cell maintenance
• p53/MDM2 axis: Arsenic induces both p53 and MDM2 phosphorylation and alters their interaction (PMID: 35829882)
• GO terms: GO:0006306 (DNA methylation), GO:0006281 (DNA repair), GO:0006915 (apoptotic process), GO:0008283 (cell proliferation), GO:0016572 (histone phosphorylation)

Cellular Processes

• Oxidative stress (GO:0006979): ROS generation from arsenic metabolism causes DNA damage
• DNA repair inhibition: Arsenic "interferes with the DNA repair process, presumably by inhibiting the ligase activity" (PMID: 1281272)
• Apoptosis dysregulation (GO:0006915): Mutations/silencing of pro-apoptotic genes allow survival of damaged cells
• Cell cycle dysregulation (GO:0007049): Altered phosphorylation of cell cycle control proteins
• Chronic inflammation: Arsenic induces sustained inflammatory responses contributing to carcinogenesis (PMID: 40533660)

Metabolic Changes

• One-carbon metabolism disruption: SAM depletion from arsenic methylation impacts methionine cycle
• Altered arsenic methylation capacity: High MMA% serves as a biomarker for cancer risk; "baseline MMA% and change in MMA% exhibited a significant dose-response relationship with cancer risk" (PMID: 19680750)
• HMDB: HMDB0001185 (S-adenosylmethionine), HMDB0000939 (S-adenosylhomocysteine)

Cancer Stem Cells

Arsenic-induced cancers are enriched for cancer stem cells: "Arsenic-induced lung and liver cancers were highly enriched for cancer stem cells, consistent with prior work with skin cancers stimulated by prenatal arsenic" (PMID: 20937726)

7. Anatomical Structures Affected

Organ Level

Secondary organ involvement: Cardiovascular system (peripheral vascular disease including Blackfoot disease, atherosclerosis), nervous system (neurotoxicity), endocrine system (diabetes), and reproductive system.

Tissue and Cell Level

• Epithelial cells (CL:0000066): Primary target across all cancer types
• Keratinocytes (CL:0000312) in skin
• Urothelial cells (CL:1001428) in bladder
• Bronchial epithelial cells (CL:0002328) in lung
• Hepatocytes (CL:0000182) in liver
• Vascular endothelial cells (CL:0000071): Angiosarcoma, Blackfoot disease
• Bile duct epithelial cells (CL:0000632): Cholangiocarcinoma

Subcellular Level

• Nucleus (GO:0005634): DNA methylation and histone modification changes
• Mitochondria (GO:0005739): Oxidative stress, ROS generation
• Cytoplasm (GO:0005737): Arsenic metabolite processing
• Endoplasmic reticulum (GO:0005783): Protein folding stress

8. Temporal Development

Onset

• Typical age of onset: Adult-onset, typically 40-70 years of age for cancers; skin lesions may appear in 30s-40s after childhood/adolescent exposure
• Onset pattern: Insidious — decades of latency between exposure and cancer diagnosis
• Critical exposure windows: In utero and early childhood exposure may be particularly carcinogenic; transplacental arsenic acts as a "complete carcinogen" in mouse models (PMID: 15276417)

Progression

Skin cancer progression: 1. Normal skin → Hyperpigmentation/depigmentation (years) 2. → Arsenical keratoses (5-10 years) 3. → Bowen's disease / SCC in situ (10-20 years) 4. → Invasive SCC or BCC (15-40+ years)

Internal cancers: Follow standard staging (AJCC TNM) for the respective cancer types.

Latency and Persistence

The most remarkable temporal feature of arsenic carcinogenesis is the extraordinary long latency:

• Northern Chile data: "lung and bladder mortality were still greatly elevated (RR = 3.38, 95% confidence interval [CI] = 3.19 to 3.58, P < .001 for lung cancer in men; RR = 4.79, 95% CI = 4.20 to 5.46, P < .001 for bladder cancer in men)" 40 years after major exposure reduction (PMID: 29069505)
• Taiwan: The gap in cancer incidence between Blackfoot disease-endemic and non-endemic areas "began to narrow approximately after the 1960 birth cohort when the tap water supply system installation commenced" (PMID: 38461779)

9. Inheritance and Population

Epidemiology

• Global exposure: >200 million people exposed to arsenic >10 μg/L in drinking water
• Global burden: Foodborne arsenic causes ~1.4 million DALYs annually for cancers (PMID: 30665120); over 56,000 deaths and >9 million DALYs from all four foodborne metals combined (PMID: 30981404)
• Hungary: Estimated 35.9-225.2 fewer cancer cases/year after water quality improvement (PMID: 36030879)

Genetic Architecture

Arsenic-related cancer susceptibility follows a multifactorial/polygenic pattern: - Not Mendelian inheritance; no single gene causes or prevents arsenic-related cancer - AS3MT variation is the strongest single genetic determinant - Penetrance is incomplete and exposure-dependent - Gene-environment interaction is the defining feature

Population Demographics

Sex ratio: Males generally at higher risk for most arsenic-related cancers. In cutaneous malignancies, male:female ratio = 11:1 in one Indian series (PMID: 24053006). However, bladder cancer mortality ratios were actually higher in women (RR=6.43) than men (RR=4.79) in the Chilean cohort (PMID: 29069505).

10. Diagnostics

Clinical Tests

• Urinary arsenic speciation (HPLC-HG-AAS): Measures iAs, MMA, DMA; the gold standard for exposure and metabolism assessment. MMA% is a potential predictor of cancer risk (PMID: 19680750)
• Hair and nail arsenic levels: Biomarkers of chronic exposure
• Blood/serum arsenic: Less commonly used; reflects recent exposure
• Imaging: Standard cancer imaging (CT, MRI, PET) for internal cancers; dermoscopy for skin lesions
• Biopsy: Histopathological examination is definitive for cancer diagnosis; arsenical keratoses show characteristic hyperkeratosis, and Bowen's disease shows full-thickness epidermal dysplasia

Biomarkers

• Urinary MMA%: Higher MMA% = poorer arsenic methylation = higher cancer risk
• Urinary DMA%: Higher DMA% = more efficient methylation = lower cancer risk
• Primary methylation index (PMI): MMA/(MMA+iAs)
• Secondary methylation index (SMI): DMA/(DMA+MMA)
• ADAM28: Overexpressed in bladder TCC from arsenic-endemic areas (PMID: 21913264)
• Aurora-A: Overexpressed in arsenic-related bladder cancer (PMID: 16338065)
• miRNAs: miR-425-5p, miR-433 as malignancy markers; miR-184, miR-576-3p as metastasis markers in skin lesions (PMID: 30114287)

Genetic Testing

• AS3MT genotyping: SNP panels for rs3740393, rs11191439, rs10748835, rs1046778 can identify individuals with inefficient arsenic metabolism
• MTHFR genotyping: For folate metabolism and arsenic interaction assessment
• Clinical utility remains primarily research-based; not yet standard of care for population screening

Differential Diagnosis

• Other causes of keratoses (actinic keratoses, seborrheic keratoses)
• Other causes of skin cancer (UV radiation, chemical exposure)
• Other causes of bladder/lung/liver cancer (smoking, hepatitis, occupational carcinogens)
• Distinguishing features: Multifocal skin lesions with characteristic arsenical pigmentation pattern; cancer occurring in endemic areas with documented arsenic exposure

11. Outcome/Prognosis

Survival and Mortality

• Lung cancer: 40-year post-exposure mortality still elevated; RR=3.38 (men) and 2.41 (women) in Chile (PMID: 29069505)
• Bladder cancer: RR=4.79 (men) and 6.43 (women) persisting 40 years post-exposure
• Skin cancer: Generally good prognosis for BCC; SCC may metastasize. Death occurred in one patient with metastatic SCC in Chinese series; all patients with localized tumors well-controlled (PMID: 39189802)
• Liver cancer (HCC, angiosarcoma): Poor prognosis consistent with general liver cancer outcomes

Morbidity

• DALYs: High per-case DALYs compared to infectious foodborne agents (PMID: 30981404)
• Comorbidities: Arsenic-exposed cancer patients often have concurrent cardiovascular disease, diabetes, peripheral vascular disease, hypertension. Significant associations noted between skin lesion severity and hypertension (POR=1.29), diabetes (POR=2.13), asthma (POR=1.55) (PMID: 23590571)

Prognostic Factors

• Cumulative arsenic exposure dose
• Urinary arsenic methylation profile (MMA% as predictor)
• AS3MT genotype
• Cancer stage at diagnosis
• Smoking co-exposure
• Nutritional status (selenium, folate)

12. Treatment

Cancer-Specific Treatment

Treatment follows standard oncological protocols for each cancer type:

Skin Cancers (MAXO: MAXO:0000004 - surgical procedure)

• Surgery: Excision is the primary treatment for SCC and BCC; 20 of 52 tumor patients opted for surgery in Chinese series (PMID: 39189802)
• Photodynamic therapy (PDT) (MAXO:0001007): Effective for Bowen's disease and superficial BCC; hematoporphyrin-mediated PDT effective for arsenic-related SCC (PMID: 38552815)
• Acitretin (retinoid): Improvement of arsenical keratosis and Bowen's disease at 1 mg/kg daily; "after the third month of treatment, improvement of lesions of arsenical keratosis and Bowen's disease were observed" (PMID: 11982642). Keratinizing papules improved in 70.59% treated with acitretin (PMID: 39189802)
• Radiotherapy: Used in 6 of 52 tumor patients in Chinese series
• 5-Fluorouracil and Imiquimod: Topical options for superficial lesions

Internal Cancers

Standard chemotherapy, targeted therapy, immunotherapy, and surgical protocols as per NCCN guidelines for lung, bladder, liver, and kidney cancers.

Arsenic as Therapeutic Agent (Paradoxical)

Arsenic trioxide (ATO, As2O3) is paradoxically a first-line treatment for acute promyelocytic leukemia (APL): - Combined with all-trans retinoic acid (ATRA), achieving 5-year overall survival >90% (PMID: 40623894) - Mechanism: Promotes degradation of PML-RARalpha fusion protein - Being explored for other cancers: HCC (induces ferroptosis) (PMID: 40402956), laryngeal SCC (inhibits PI3K/AKT via miR-573) (PMID: 40721473) - ATO shows a "dual effect" — carcinogenic for solid tumors but therapeutic for hematologic malignancies; arsenic water exposure was negatively associated with lymphoma and leukemia incidence (PMID: 35570949)

Chemoprevention

• Selenium supplementation: Blocks arsenic cancer enhancement in mice by preventing arsenic accumulation in skin; selenium-bis(S-glutathionyl) arsinium ion formation in liver may be the mechanism (PMID: 18560523)
• Vitamin E and selenium trial (BEST): 2x2 factorial RCT of 7,000 adults with arsenical skin lesions testing alpha-tocopherol (100 mg/day) and L-selenomethionine (200 ug/day) for nonmelanoma skin cancer prevention (PMID: 23590571)

13. Prevention

Primary Prevention (MAXO:0000001 - prevention)

Water mitigation is the most effective intervention:

• Clean water supply: Taiwan Blackfoot disease area — tap water installation beginning in the 1960s led to declining cancer gap for birth cohorts born after mitigation (PMID: 38461779)
• Hungary DWQIP: Arsenic in water reduced from median 3.0 to 2.15 μg/L, associated with 35.9-225.2 fewer cancer cases/year (PMID: 36030879)
• Point-of-use arsenic filters: Strong Heart Water Study showed 47% reduction in urinary arsenic with filters and mHealth program (PMID: 38534131)
• WHO guideline: Maximum 10 μg/L arsenic in drinking water
• Smoking cessation: Given the synergistic interaction, smoking cessation is critical for arsenic-exposed populations

Secondary Prevention

• Screening of exposed populations: Urinary arsenic speciation testing
• Skin surveillance: Regular dermatological examination for arsenical keratoses and early malignant changes
• Cancer screening: Standard screening protocols for bladder (urine cytology), lung (low-dose CT in high-risk), and liver cancer (ultrasound, AFP)

Tertiary Prevention

• Long-term follow-up: Given 40+ year latency, patients with history of arsenic exposure require lifelong cancer surveillance
• Nutritional supplementation: Selenium, folate, B vitamins to support arsenic methylation and reduce oxidative stress
• Comorbidity management: Monitor and treat associated cardiovascular disease and diabetes

Public Health Interventions

• Water quality monitoring and regulation
• Well water testing programs (especially for private wells)
• Community education about arsenic contamination sources
• Agricultural practices to reduce arsenic in rice and other crops
• Regulation of arsenic in traditional medicines

14. Other Species / Natural Disease

Species Affected

Arsenic affects essentially all vertebrate species exposed to sufficient doses: - Mus musculus (NCBI Taxon: 10090): Primary experimental model - Rattus norvegicus (NCBI Taxon: 10116): Used for urinary bladder and liver carcinogenesis studies - Danio rerio (NCBI Taxon: 7955): Zebrafish models for developmental toxicity

Comparative Biology

• AS3MT orthologs are conserved across vertebrates; NCBI Gene IDs: Human AS3MT (57412), Mouse As3mt (57344), Rat As3mt (140917)
• Arsenic metabolism pathways are evolutionarily conserved, though methylation efficiency varies by species
• Mice do not spontaneously develop cancer from arsenic alone at typical exposure levels without co-promoters or gestational exposure, limiting direct comparison to human carcinogenesis

15. Model Organisms

Mouse Models

Transplacental Carcinogenesis (C3H mice)

• Pregnant mice exposed to arsenite (42.5 or 85 ppm) from gestation day 8-18
• Offspring develop HCC, adrenal tumors, lung carcinoma, ovarian tumors as adults
• "Inorganic arsenic could act as a 'complete' transplacental carcinogen in mice" (PMID: 15276417)

Whole-Life Exposure (CD1 mice)

• Arsenic exposure at 6, 12, or 24 ppm from pre-breeding through adulthood
• Dose-related increases in lung adenocarcinoma, HCC, gallbladder tumors, uterine and ovarian carcinomas
• "Whole-life arsenic exposure induced tumors at dramatically lower external doses than in utero arsenic only while more realistically duplicating human exposure" (PMID: 20937726)

p53 +/- Knockout Models

• DMA carcinogenicity in p53 heterozygous knockout C57BL/6J mice
• Significant early tumor induction in both p53+/- and wild-type mice (PMID: 12584185)

UV Co-Carcinogenesis (Hairless mice)

• Arsenite enhanced UVR carcinogenesis >5-fold; selenium blocked enhancement (PMID: 18560523)

Rat Models

• DMA carcinogenesis in urinary bladder and liver (promotion and initiation)
• Multi-organ promotion bioassays demonstrating promoting/initiating activity
• "The adverse effects of arsenic occurred either by promoting and initiating carcinogenesis" (PMID: 15276416)

Cell Line Models

• A549 (lung adenocarcinoma): Used for MDM2/p53 pathway studies (PMID: 35829882)
• 16HBE (human bronchial epithelial): Arsenic transformation studies
• E7 (immortalized bladder): Aurora-A upregulation by arsenic (PMID: 16338065)
• TU212, TU686, AMC-HN-8 (laryngeal SCC): ATO therapeutic studies (PMID: 40721473)

Model Limitations

• Mice do not develop skin cancer from arsenic alone (require UV co-promotion or transplacental exposure)
• Species differences in arsenic methylation efficiency
• Laboratory exposure levels often higher than environmental human exposures
• Short lifespan limits study of decades-long latency observed in humans

Key Findings with Statistical Evidence

Finding 1: Arsenic is an IARC Group 1 Human Carcinogen with Strong Dose-Response Relationships

Inorganic arsenic is definitively established as causing cancers of the skin, lung, bladder, liver, and kidney. The epidemiological evidence demonstrates clear dose-response relationships:

• Bladder cancer: ORs for quartiles of average arsenic concentrations before 1971 (<11, 11-90, 91-335, and >335 μg/L) were 1.00, 1.36, 3.87, and 6.50 respectively (PMID: 23355602)
• Lung cancer: OR=4.32 (95% CI 2.60-7.17) at highest exposure levels
• Mortality persistence: Lung cancer RR=3.38 and bladder cancer RR=4.79 in men, 40 years after exposure cessation (PMID: 29069505)
• Negative findings: No increased risk found for breast cancer (PMID: 40629209) or prostate cancer (PMID: 40956283) even at high exposures, suggesting tissue-specific carcinogenicity

Finding 2: AS3MT Polymorphisms Are the Primary Genetic Determinant of Cancer Susceptibility

The AS3MT gene at 10q24.32 contains the strongest genetic determinants of arsenic metabolism and cancer risk:

• GWAS identified genome-wide significant variants (P<5x10^-8) near AS3MT for arsenic metabolite profiles (PMID: 22383894)
• rs3740393 carriers had lower %MMA (-1.9%), higher %DMA (+4.0%), and markedly lower bladder cancer OR=0.3 (95% CI: 0.1-0.6) (PMID: 28640505)
• AS3MT haplotype-cancer risk relationship provides mechanistic evidence for causality: "the fact that AS3MT haplotype status modified arsenic metabolism, and in turn the arsenic-related BCC risk, supports a causal relationship" (PMID: 25156000)

Finding 3: Epigenetic Dysregulation Is the Central Carcinogenic Mechanism

Arsenic carcinogenesis is fundamentally epigenetic rather than mutagenic:

• SAM depletion through arsenic methylation creates "an epigenetic disequilibrium" (PMID: 25898228)
• p16 promoter hypermethylation: 42% in exposed vs 2% in controls (PMID: 17479413)
• Loss of H4K16ac as a cancer hallmark (PMID: 27352015)
• Stage-specific miRNA profiles differentiate premalignant from malignant lesions (PMID: 30114287)
• Arsenic increases chromosomal aberrations but does NOT cause point mutations (PMID: 11885915)

Finding 4: Water Mitigation Reduces Cancer Burden with Decades-Long Latency

Water supply interventions are effective but slow to show full benefit:

• Taiwan: Cancer incidence gap narrowed for birth cohorts after tap water installation in the 1960s (PMID: 38461779)
• Hungary: 35.9-225.2 fewer cancer cases/year after DWQIP implementation (PMID: 36030879)
• Chile: Benefits still incompletely realized 40 years later, with persistent elevated cancer mortality (PMID: 29069505)
• Point-of-use filters: 47% reduction in urinary arsenic in American Indian communities (PMID: 38534131)

Finding 5: Arsenic-Smoking Synergism Substantially Amplifies Lung Cancer Risk

The interaction between arsenic and tobacco smoking is more than additive:

• "The joint effect from both exposures consistently exceeded the sum of the separate effects by about 70 to 130%" (PMID: 1554806)
• At least 30-54% of lung cancers in co-exposed individuals cannot be attributed to either factor alone
• Synergism is dose-dependent, primarily at arsenic >100 μg/L (PMID: 36901176)

Evidence Base

Landmark Epidemiological Studies

Key Genetic/Mechanistic Studies

Limitations and Knowledge Gaps

1. Low-dose risk characterization: The dose-response relationship at low arsenic levels (<50 μg/L) remains debated. Multiple studies support threshold or "hockey-stick" models rather than linear no-threshold assumptions (PMID: 33781801), but this remains controversial.

2. Cancer-type specificity: Why arsenic causes cancer in some organs (skin, lung, bladder) but apparently not others (breast, prostate) is poorly understood. Negative findings for breast cancer (OR=1.10, non-significant at highest exposure) (PMID: 40629209) and prostate cancer (PMID: 40956283) highlight this gap.

3. Epigenetic specificity: While global epigenetic changes are well-documented, the specific epigenetic "driver" events that initiate carcinogenesis vs. passenger events remain unclear.

4. Dual role of arsenic: The paradox that arsenic is carcinogenic for solid tumors but therapeutic for APL and apparently protective against lymphoma/leukemia (PMID: 35570949) is not fully explained.

5. Biomarker validation: Urinary MMA% as a cancer risk predictor needs further validation in prospective cohorts, and confounding by dietary arsenosugars must be addressed (PMID: 37881591).

6. Population-specific susceptibility: Different populations show varying sensitivity to arsenic, but the genetic architecture beyond AS3MT is poorly characterized.

7. Latency mechanism: Why cancer risk persists 40+ years after exposure cessation is not mechanistically explained — whether this reflects irreversible epigenetic reprogramming, cancer stem cell establishment, or ongoing effects of tissue-deposited arsenic.

Proposed Follow-up Experiments/Actions

1. Prospective epigenome-wide association studies (EWAS) in arsenic-exposed cohorts with cancer outcomes to identify specific epigenetic driver events that predict cancer development before clinical disease.

2. Multi-omics integration studies (genomics, epigenomics, transcriptomics, metabolomics) in matched arsenic-exposed cancer and non-cancer tissues to build causal models of tissue-specific carcinogenesis.

3. AS3MT pharmacogenomics implementation study: Evaluate whether AS3MT genotyping can improve risk stratification and targeted screening in arsenic-endemic populations.

4. Longitudinal selenium chemoprevention trials: Results from the BEST trial (PMID: 23590571) should inform larger trials of selenium and antioxidant supplementation in high-risk populations.

5. Low-dose epidemiological studies: Large-scale prospective cohorts in populations exposed to arsenic at 10-50 μg/L to resolve the low-dose risk characterization debate and inform drinking water standards.

6. Single-cell epigenomic profiling of arsenic-transformed cells to identify the cancer-initiating cell populations and their epigenetic signatures, potentially explaining the cancer stem cell enrichment observed in arsenic cancers.

7. Point-of-use water treatment scale-up: Expand programs like SHWS (PMID: 38534131) with long-term cancer outcome monitoring to quantify the public health benefit of household-level arsenic mitigation.

8. miRNA-based liquid biopsy development: Validate miR-425-5p, miR-433, miR-184, and miR-576-3p as circulating biomarkers for early detection of arsenic-related malignancies.

Report compiled from systematic literature review of 100 publications spanning epidemiology, genetics, epigenetics, toxicology, and public health. All findings supported by peer-reviewed evidence with PMIDs provided.